SecBot SecBot
6-K ·Filed Jul 14, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed4mo ago SEC0001654954-26-006640
Notable filing: 6-K
Actionable Insight • Neutral

No trading action warranted. This is a routine administrative filing with no informational content for the stock. Monitor next quarterly earnings for fundamental developments.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$51.25
T+0 close · Jul 14, 2026 · via day close
Latest settled
−8.25%
T+60 · $47.02
Vs SPY
−11.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $51.25entry
  2. T+1 · 4mo ago +0.39%α −0.01% · $51.45
  3. T+5 · 4mo ago −2.36%α −1.07% · $50.04
  4. T+20 · 3mo ago −0.68%α −3.17% · $50.90
  5. T+60 · 6w ago −8.25%α −11.63% · $47.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine 6-K reporting that multiple PDMRs (including the CEO, CFO, and other senior executives) acquired ordinary shares and ADSs through the automatic reinvestment of dividends paid on July 9, 2026. The transactions are mechanical dividend reinvestments, not discretionary open-market purchases, and carry no signaling value. The filing is administrative and has no material impact on the company's financial outlook or stock price.

Key Facts

  • Dividend reinvestment transactions occurred on July 9, 10, and 13, 2026.
  • CEO Luke Miels acquired 20.727 ordinary shares at £19.6297 via dividend reinvestment.
  • CFO Julie Brown increased notional interest by 1,636 ordinary shares at £19.5950 via the Deferred Annual Bonus Plan.
  • President Corporate Development David Redfern acquired 5,803.725 ordinary shares at £19.6297 via dividend reinvestment.
  • Chief Digital and Technology Officer Shobie Ramakrishnan increased notional interest by 324 ADSs at $52.47 via the Deferred Annual Bonus Plan.
  • All transactions were automatic, not discretionary open-market purchases.

Financial Impact

No material financial impact. Total aggregate value of all reported transactions is approximately £250,000 (based on share counts and prices in the filing).

Risk Factors

  • None from this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006640
Document: 0001654954-26-006640-index-headers.html0001654954-26-006640
Document: 0001654954-26-006640-index.html0001654954-26-006640
Document: 0001654954-26-006640.txt0001654954-26-006640

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026